Various vaccines against COVID-19 have been developed since SARS-CoV-2 emerged at the end of 2019. Their emergency administration in healthcare settings has been accompanied by numerous adverse effects. A case of Guillain-Barré syndrome following vaccination with Covishield is presented here to highlight this possible adverse condition.
Learning points: Guillain-Barré Syndrome (GBS) is a very rare complication after vaccination against SARS-CoV-2.The key concepts related to the understanding, management and outcomes of patients with GBS are discussed.
Keywords: AstraZeneca; ChAdOx1; Covishield; GBS; Guillain-Barré syndrome; coronavirus; pandemic; vaccine.
© EFIM 2021.